About: Purified coronavirus Spike protein nanoparticles induce coronavirus neutralizing antibodies in mice

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Purified coronavirus Spike protein nanoparticles induce coronavirus neutralizing antibodies in mice Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Purified coronavirus Spike protein nanoparticles induce coronavirus neutralizing antibodies in mice
Creator	Frieman, Matthew Taylor, Justin Liu, Ye Massare, Michael Mu, Haiyan Glenn, Gregory Smith, Gale Coleman, Christopher Flyer, David
Source	Elsevier; Medline; PMC
abstract	Development of vaccination strategies for emerging pathogens are particularly challenging because of the sudden nature of the emergence of these viruses and the long process needed for traditional vaccine development. Therefore, there is a need for development of a rapid method of vaccine development that can respond to emerging pathogens in a short time frame. The emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003 and Middle East respiratory syndrome (MERS-CoV) in late 2012 demonstrate the importance of coronaviruses as emerging pathogens. The spike glycoproteins of coronaviruses reside on the surface of the virion and are responsible for virus entry. The spike glycoprotein is the major immunodominant antigen of coronaviruses and has proven to be an excellent target for vaccine designs that seek to block coronavirus entry and promote antibody targeting of infected cells. Vaccination strategies for coronaviruses have involved live attenuated virus, recombinant viruses, non-replicative virus-like particles expressing coronavirus proteins or DNA plasmids expressing coronavirus genes. None of these strategies has progressed to an approved human coronavirus vaccine in the ten years since SARS-CoV emerged. Here we describe a novel method for generating MERS-CoV and SARS-CoV full-length spike nanoparticles, which in combination with adjuvants are able to produce high titer antibodies in mice.
has issue date	2014-05-01(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2014.04.016
bibo:pmid	24736006
has license	bronze-oa
sha1sum (hex)	43e23cb209c2ee3419efcca67f10e66c790a5e4d
schema:url	https://doi.org/10.1016/j.vaccine.2014.04.016
resource representing a document's title	Purified coronavirus Spike protein nanoparticles induce coronavirus neutralizing antibodies in mice
has PubMed Central identifier	PMC4058772
has PubMed identifier	24736006
schema:publication	Vaccine
resource representing a document's body	covid:43e23cb209c2ee3419efcca67f10e66c790a5e4d#body_text
is schema:about of	named entity 'vaccine' named entity 'sudden' named entity 'NATURE' named entity 'NEED FOR' named entity 'RAPID METHOD' named entity 'THEIR' named entity 'SHORT' named entity 'VACCINE DEVELOPMENT' named entity 'MICE' named entity 'PROTEIN ' named entity 'IS A' named entity 'STRATEGIES' named entity 'TIME FRAME' named entity 'PURIFIED' named entity 'SPIKE PROTEIN' named entity 'NANOPARTICLES' named entity 'INDUCE' named entity 'NEUTRALIZING ANTIBODIES' named entity 'PROCESS' named entity 'EMERGENCE' named entity 'CORONAVIRUS' named entity 'SUDDEN' named entity 'VACCINATION' named entity 'DEVELOPMENT' named entity 'LONG' named entity 'RESPOND TO' named entity 'NEEDED' named entity 'TRADITIONAL' named entity 'PATHOGENS' covid:arg/43e23cb209c2ee3419efcca67f10e66c790a5e4d named entity 'vaccine' named entity 'nature' named entity 'short time' named entity 'nanoparticles' named entity 'neutralizing antibodies' named entity 'MERS-CoV' named entity 'SARS-CoV' named entity 'eosinophilia' named entity 'MERS-CoV' named entity 'MERS-CoV' named entity 'Sigma-Aldrich' named entity 'genomes' named entity 'SARS-CoV' named entity 'serum' named entity 'China' named entity 'protein' named entity 'MERS-CoV' named entity 'GMT' named entity 'inoculation' named entity 'protein sequence' named entity 'adjuvant' named entity 'homologous' named entity 'China' named entity 'Middle East' named entity 'coronaviruses' named entity 'adjuvant' named entity 'GMT' named entity 'protein' named entity 'Kingdom of Saudi Arabia' named entity 'MERS-CoV' named entity 'recombinant' named entity 'neutralizing antibody' named entity 'Nuclear Polyhedrosis Virus' named entity 'coronaviruses' named entity 'SARS' named entity 'infection' named entity 'polyhedrin' named entity 'baculovirus' named entity 'VLP' named entity 'Spike proteins' named entity 'insect' named entity 'serological' named entity 'vaccinia virus'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software